Urological Surgery
Conditions
Interventions
Experimental group:Endoscopic surgical system C1000 for urological surgery
Sponsors
The First Medical Center of Chinese PLA General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Age from 18 to 80 years,and the gender is not limited. 2. Body mass index(BMI): 18~ 30 kg/m2. 3. Those who need to receive urological surgery. 4. The subject voluntarily participates in the clinical trial,and agrees or is agreed by the guardian to sign an informed consent form. 5. Those who are able to cooperate and complete the study follow-up and related examinations;
Exclusion criteria
Exclusion criteria: 1.Preoperative imaging shows distant metastasis. 2.Those with a history of urological surgery or a history of other malignancies who have been judged by the investigator to be unsuitable for enrollment. 3.Those who are expected to be unable to tolerate pneumoperitoneum or long-term Trendelenburg’s Position, or have diseases that cannot cooperate in the intraoperative position, such as spinal deformity, ankylosing spondylitis, etc.; 4.Those with severe comorbidities (heart, lung, liver, brain, kidney and other diseases) and weak constitution that cannot tolerate general anesthesia or surgery; 5. Those with severe bleeding tendency or coagulation dysfunction; 6. Patients who have been using anticoagulant and antiplatelet aggregation drugs for a long time, or those who have stopped anticoagulant and antiplatelet aggregation drugs for less than 1 week before surgery (except for preoperative prophylactic use of low molecular weight heparin); 7.Those who are in the active phase of infectious diseases or have other severe non-communicable infections; 8. Immunodeficiency virus (HIV) antibody positive, hepatitis B surface antigen (HbsAg) positive, hepatitis C virus (HCV) antibody positive,Treponema pallidum positive patients; 9. Those with severe allergies, suspected or determined to have alcohol, drugs or drug addiction; 10.Those with a history of epilepsy or psychiatric illness or cognitive impairment; 11. Women who are pregnant, breastfeeding, or planning to become pregnant during the trial, or male or female patients who do not wish to use barrier contraception during the trial; 12. Participated in any other clinical trial (except non-interventional trials) within 3 months prior to signing the informed consent form, planned to undergo other major surgical treatment during the trial, or was unable to recover from the side effects of previous surgery; 13. Other circumstances that the investigator deems inappropriate to participate in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Success rate of operation; | — |
Secondary
| Measure | Time frame |
|---|---|
| Installation time (min);Operation time (min);Estimated blood loss (Intraoperarion);Surgeon's satisfaction;Length of hospital stay;Comprehensive Complication Index (CCI);Rate of postive surgical margin;Changes in prostate specific antigen concentration;Warm ischemic time;Changes in renal function;Remission of hydronephrosis; | — |
Countries
China
Contacts
Public ContactZhang Xu
The First Medical Center of Chinese PLA General Hospital
Outcome results
None listed